Global Neuraminidase Inhibitor 麻豆原创 Research Report 2024

Publication ID:

PB506249800

Publication Date:

June 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Influenza viruses are characterized by two surface glycoproteins i.e. hemagglutinnin and neuraminidase. Neuraminidase are the antigens which play an important role in defining the particular strain of influenza. Dosage and safety of neuraminidase inhibitors are the two main parameters, affecting the growth of neuraminidase inhibitors market. The various symptoms of influenza are cough, running nose, fever, headache, fatigue, chills etc. The neuraminidase are recommended for the treatment of the symptoms after the forty eight hours of start of these symptoms.
There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.
The global Neuraminidase Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuraminidase Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuraminidase Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst and Daiichi Sankyo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuraminidase Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuraminidase Inhibitor.
Report Scope
The Neuraminidase Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuraminidase Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuraminidase Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Segment by Type
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neuraminidase Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Neuraminidase Inhibitor 麻豆原创 Overview
1.1 Product Overview and Scope of Neuraminidase Inhibitor
1.2 Neuraminidase Inhibitor Segment by Type
1.2.1 Global Neuraminidase Inhibitor 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Neuraminidase Inhibitor Segment by Application
1.3.1 Global Neuraminidase Inhibitor 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Stores
1.3.5 Others
1.4 Global Neuraminidase Inhibitor 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Neuraminidase Inhibitor Revenue 2019-2030
1.4.2 Global Neuraminidase Inhibitor Sales 2019-2030
1.4.3 Global Neuraminidase Inhibitor 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neuraminidase Inhibitor 麻豆原创 Competition by Manufacturers
2.1 Global Neuraminidase Inhibitor Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Neuraminidase Inhibitor Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Neuraminidase Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Neuraminidase Inhibitor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neuraminidase Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuraminidase Inhibitor, Product Type & Application
2.7 Neuraminidase Inhibitor 麻豆原创 Competitive Situation and Trends
2.7.1 Neuraminidase Inhibitor 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neuraminidase Inhibitor Players 麻豆原创 Share by Revenue
2.7.3 Global Neuraminidase Inhibitor 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuraminidase Inhibitor Retrospective 麻豆原创 Scenario by Region
3.1 Global Neuraminidase Inhibitor 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neuraminidase Inhibitor Global Neuraminidase Inhibitor Sales by Region: 2019-2030
3.2.1 Global Neuraminidase Inhibitor Sales by Region: 2019-2024
3.2.2 Global Neuraminidase Inhibitor Sales by Region: 2025-2030
3.3 Global Neuraminidase Inhibitor Global Neuraminidase Inhibitor Revenue by Region: 2019-2030
3.3.1 Global Neuraminidase Inhibitor Revenue by Region: 2019-2024
3.3.2 Global Neuraminidase Inhibitor Revenue by Region: 2025-2030
3.4 North America Neuraminidase Inhibitor 麻豆原创 Facts & Figures by Country
3.4.1 North America Neuraminidase Inhibitor 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neuraminidase Inhibitor Sales by Country (2019-2030)
3.4.3 North America Neuraminidase Inhibitor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neuraminidase Inhibitor 麻豆原创 Facts & Figures by Country
3.5.1 Europe Neuraminidase Inhibitor 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neuraminidase Inhibitor Sales by Country (2019-2030)
3.5.3 Europe Neuraminidase Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuraminidase Inhibitor 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Neuraminidase Inhibitor 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neuraminidase Inhibitor Sales by Country (2019-2030)
3.6.3 Asia Pacific Neuraminidase Inhibitor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Neuraminidase Inhibitor 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Neuraminidase Inhibitor 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neuraminidase Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America Neuraminidase Inhibitor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuraminidase Inhibitor 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Neuraminidase Inhibitor 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neuraminidase Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neuraminidase Inhibitor Sales by Type (2019-2030)
4.1.1 Global Neuraminidase Inhibitor Sales by Type (2019-2024)
4.1.2 Global Neuraminidase Inhibitor Sales by Type (2025-2030)
4.1.3 Global Neuraminidase Inhibitor Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Neuraminidase Inhibitor Revenue by Type (2019-2030)
4.2.1 Global Neuraminidase Inhibitor Revenue by Type (2019-2024)
4.2.2 Global Neuraminidase Inhibitor Revenue by Type (2025-2030)
4.2.3 Global Neuraminidase Inhibitor Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Neuraminidase Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neuraminidase Inhibitor Sales by Application (2019-2030)
5.1.1 Global Neuraminidase Inhibitor Sales by Application (2019-2024)
5.1.2 Global Neuraminidase Inhibitor Sales by Application (2025-2030)
5.1.3 Global Neuraminidase Inhibitor Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Neuraminidase Inhibitor Revenue by Application (2019-2030)
5.2.1 Global Neuraminidase Inhibitor Revenue by Application (2019-2024)
5.2.2 Global Neuraminidase Inhibitor Revenue by Application (2025-2030)
5.2.3 Global Neuraminidase Inhibitor Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Neuraminidase Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 F. Hoffman-La Roche
6.3.1 F. Hoffman-La Roche Corporation Information
6.3.2 F. Hoffman-La Roche Description and Business Overview
6.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
6.3.5 F. Hoffman-La Roche Recent Developments/Updates
6.4 BioCryst
6.4.1 BioCryst Corporation Information
6.4.2 BioCryst Description and Business Overview
6.4.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BioCryst Neuraminidase Inhibitor Product Portfolio
6.4.5 BioCryst Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuraminidase Inhibitor Industry Chain Analysis
7.2 Neuraminidase Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuraminidase Inhibitor Production Mode & Process
7.4 Neuraminidase Inhibitor Sales and 麻豆原创ing
7.4.1 Neuraminidase Inhibitor Sales Channels
7.4.2 Neuraminidase Inhibitor Distributors
7.5 Neuraminidase Inhibitor Customers
8 Neuraminidase Inhibitor 麻豆原创 Dynamics
8.1 Neuraminidase Inhibitor Industry Trends
8.2 Neuraminidase Inhibitor 麻豆原创 Drivers
8.3 Neuraminidase Inhibitor 麻豆原创 Challenges
8.4 Neuraminidase Inhibitor 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.